Novo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +4.47%
- EPS
- −18.7%
- Free cash flow
- +71.6%
- Total debt
- +44.4%
Quarter to June 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) EV/FCF
As of 5 November 2026, Novo Nordisk A/S (NVO) trades at a EV/FCF of 25.4×. Over the past ten years it has ranged from 12.8× (March 2017) to 89.6× (June 2024); the current reading is higher than 36% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 54.9× | 40.90% |
| FY2024 | 38.9× | (13.37%) |
| FY2023 | 44.9× | 31.60% |
| FY2022 | 34.2× | 0.12% |
| FY2021 | 34.1× | (4.01%) |
| FY2020 | 35.5× | 39.54% |
| FY2019 | 25.5× | 14.95% |
| FY2018 | 22.2× | (16.42%) |
| FY2017 | 26.5× | 79.81% |
| FY2016 | 14.7× | (52.20%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 29.8× | (20.40%) |
| Mar 2026 | 37.4× | (31.74%) |
| Dec 2025 | 54.9× | 101.83% |
| Sep 2025 | 27.2× | (21.06%) |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| SNY Sanofi compare | 7.5× |
| GSK GSK PLC Sponsored ADR compare | 14.6× |
| GILD Gilead Sciences, Inc. compare | 16.5× |
| BMY Bristol Myers Squibb Company compare | 17.2× |
| PFE Pfizer Inc. compare | 19.9× |
| NVS Novartis AG compare | 24.4× |
| NVO Novo Nordisk A/S | 25.4× |
| AMGN Amgen Inc. compare | 31.8× |
| AZN AstraZeneca PLC compare | 49.5× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on NVO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement